Genetic Test For Chronic Hepatitis C-Related Cirrhosis
Filed in archive Diagnostics, Methodologies and Instrumentation , Genomics, Proteomics and Bioinformatics , Meetings and Other Events on April 27, 2006
After 3-year research study, Celera Genomics announced having identified seven single nucleotide polymorphisms (SNPs) that predicts the risk of cirrhosis in patients with chronic hepatitis-C (CHC). The results were based on a study of samples from more than 1,500 individuals infected with CHC, ran through Celera's functional genome scan for SNPs. Results also showed that these 7 SNPs were more effective in predicting the likelihood of cirrhosis than an evaluation of clinical risk factors such as age, gender and daily alcohol consumption.
"This study confirms that the genetic makeup of each patient is the most important factor in determining which patients with chronic HCV are likely to develop fibrosis progression to cirrhosis," said Mitchell L. Shiffman, M.D., Professor of Medicine, Chief, Hepatology, Medical Director, Liver Transplant Program, Virginia Commonwealth University Medical Center, and a collaborator and co-author of the study. "These data are very likely to change the way in which we evaluate and select patients for anti-viral therapy."
"Use of this information to select and treat the patients at highest risk for progression earlier may help prevent irreversible liver damage and improve patient compliance with therapy," said Kathy Ordoñez, President of Celera Genomics. "These results may also enable more cost-effective and timely demonstration of efficacy for new drug therapies by enriching trials with those individuals more likely to suffer from disease progression."
The results of the study will be presented at the 41st annual meeting of The European Association for the Study of the Liver, on April 28, 2006 in Vienna, Austria.
In a report published at the New York Times, Celera president was quoted saying that the company hope to license a laboratory test based on these study, and estimated the test to cost about $1,000. Add another one to the growing number of genetic diagnostic tests.
Read the full story: Genetic Test to Give Clues on Treatment of Hepatitis C
"Use of this information to select and treat the patients at highest risk for progression earlier may help prevent irreversible liver damage and improve patient compliance with therapy," said Kathy Ordoñez, President of Celera Genomics. "These results may also enable more cost-effective and timely demonstration of efficacy for new drug therapies by enriching trials with those individuals more likely to suffer from disease progression."
Tags: genomics diagnostics biotech genetic test genetic+test chronic+hepatitis test+chronic
Vote for Genetic Test For Chronic Hepatitis C-Related Cirrhosis:
|
Rating: 6.00 out of 4 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
